GLP-1 Weight-Loss Drugs Require Careful Medical Oversight, UK Regulator Warns

The UK Medicines and Healthcare products Regulatory Agency warns that GLP-1 weight-loss medications require medical supervision, careful dose monitoring, and…

Submit Your Paper to GMJ

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.

When Demand Outpaces Safety: The Regulatory Failure of Compounded GLP-1 Medications

Compounded GLP-1 medications contain untested additive combinations reaching millions of patients globally. Regulatory systems have failed to establish safety standards…

U.S. Measles Cases Exceed Entire 2025 Total With Five Months Remaining in 2026

Measles cases in the United States have surpassed the entire 2025 annual total by mid-July 2026, with five months remaining…

FDA Panel Backs Two Peptides for Compounding, Rejects Third in Closely Divided Vote

A U.S. FDA advisory panel voted narrowly to permit compounding of two peptides while rejecting a third, reflecting ongoing regulatory…

Serum Biomarkers Outperform Imaging for Early MASLD Risk Detection, Nature Medicine Study Finds

A prospective validation study in Nature Medicine demonstrates that serum biomarkers outperform imaging for detecting steatohepatitis risk in MASLD, while…

NHS £10bn AI Investment Lacks Robust Evidence Framework, BMJ Analysis Finds

England's £10 billion NHS AI investment promises £41 billion in benefits, but The BMJ warns that digital health systems face…

Wildfire Smoke and Health Risks: What North American Cities Face During Peak Fire Season

Wildfire smoke from Canadian wildfires blanketed major North American cities in July 2026, with PM2.5 concentrations exceeding 600 µg/m³—nearly three…

Stanford researchers identify natural appetite-suppressing molecule with potential advantages over semaglutide

Stanford Medicine researchers have identified BRP, a naturally occurring molecule that suppresses appetite through brain-targeted mechanisms distinct from semaglutide, potentially…

Zaire Ebola vaccine shows partial cross-protection against Bundibugyo strain in ongoing outbreak

The licensed Zaire ebolavirus vaccine may provide partial cross-protection against Bundibugyo ebolavirus, offering a limited pharmaceutical option in the ongoing…

GMJ BriefsView all →
Operated by the Public Health Institute of Georgia (PHIG) · non-profit, ID 404407815 · 3 Betlemi Rise, Tbilisi 0105, Georgia · editor@gmj.ge · Policy Framework · Legal notice · Privacy · Accessibility · Part of the PHIG network